CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis

Meyer, Hans‐Jonas; Wienke, Andreas; Surov, Alexey

doi:10.1016/j.urolonc.2021.08.009

Cited by 9 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, LSMM predicts worse overall survival in gastric cancer, HR = 2.12, CI 95% (1.89–2.38) ( 15 ). Similar findings are known for pancreatic cancer, colorectal cancer, esophageal cancer, prostatic cancer, and malignant hematological diseases ( 16 , 17 , 18 , 19 , 20 ). In intensive care units, LSMM predicts short-term mortality, HR = 2.78 CI 95% (2.05-3.75) ( 21 ).…”

Section: Discussionsupporting

confidence: 83%

Prognostic Role of the Pectoralis Musculature in Patients with COVID-19. A Multicenter Study

et al. 2023

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

Prognostic Role of the Pectoralis Musculature in Patients with COVID-19. A Multicenter Study

et al. 2023

Self Cite

View full text Add to dashboard Cite

“…[1][2][3][4][5] Low muscle mass has been consistently associated with adverse clinical outcomes, such as greater mortality, dose-limiting toxicity, length of hospitalization, and postoperative complications. 2,3,[6][7][8][9] Quality of life is also affected following cancer diagnosis and is positively associated with muscle mass. [10][11][12][13][14] The pathophysiology of muscle wasting in cancer is multifactorial and not yet fully understood.…”

Section: Introductionmentioning

confidence: 99%

“… 1 , 2 , 3 , 4 , 5 Low muscle mass has been consistently associated with adverse clinical outcomes, such as greater mortality, dose‐limiting toxicity, length of hospitalization, and postoperative complications. 2 , 3 , 6 , 7 , 8 , 9 Quality of life is also affected following cancer diagnosis and is positively associated with muscle mass. 10 , 11 , 12 , 13 , 14 …”

Section: Introductionmentioning

confidence: 99%

Effects of β‐hydroxy β‐methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review

Prado

Orsso

Pereira

et al. 2022

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Low muscle mass is prevalent among patients with cancer and a predictor of adverse clinical outcomes. To counteract muscle loss, β-hydroxy β-methylbutyrate (HMB) supplementation has been proposed as a potential therapy for older adults and various diseases states. This systematic review aimed to investigate the effects and safety of HMB supplementation in relation to muscle mass and function and other clinical outcomes in patients with cancer. A systematic search of MEDLINE, CINAHL, Embase, Cochrane Central Register of Controlled Trials, Scopus, ProQuest, and grey literature for reports published from inception to December 2021 was conducted. Included studies provided supplements containing any dose of HMB to adult patients with active cancer. A synthesis without meta-analysis was conducted using a vote-counting approach based solely on the direction of the effect (i.e. regardless of statistical significance). Risk of bias was assessed for each outcome domain, and evidence from higher-quality studies (i.e. those with either low or moderate risk of bias) was examined. Safety was evaluated using both lower-quality and higher-quality studies. Fifteen studies were included, in which six were randomized controlled trials in patients with various cancer types and treatments. Studies prescribed HMB combined with amino acids (73.3%), HMB in oral nutritional supplements (20.0%), or both supplement types (6.7%); Ca-HMB doses of 3.0 g/day were provided in 80.0% of the studies. Four studies had high risk of bias across all outcome domains. Considering the higher-quality studies, evidence of a beneficial effect of HMB supplementation was found in four of four studies for muscle mass, two of two for muscle function, three of three for hospitalization, and five of seven for survival. In contrast, no beneficial effects of HMB on quality of life or body weight was found in two of four and three of five studies, respectively. A limited number of higher-quality studies evaluating the impact of HMB on cancer therapy-related toxicity, inflammation, and tumour response were observed. No serious adverse effects directly related to the nutrition intervention were reported. Although limited, current evidence suggests that HMB supplementation has a beneficial effect on muscle mass and function in patients with cancer. Well-designed trials are needed to further explore the clinical benefit of HMB supplementation in this patient population.

show abstract

“…The occurrence of sarcopenia has also been related to the increased risk of postsurgical complications [ 43 ] and systemic treatment toxicity [ 44 ], leading to the notion that assessing the sarcopenic status before treatment may guide customised strategies and support tailored treatment decision-making. A robust prognostic impact of sarcopenia has also been shown in PC, in which this condition is present in over 60% of patients [ 21 , 45 , 46 ]. However, at the later stages of the disease (i.e., in heavily pre-treated mCRPC), the prevalence of sarcopenia can be considerably increased [ 21 , 45 ].…”

Section: Discussionmentioning

confidence: 99%

“…A robust prognostic impact of sarcopenia has also been shown in PC, in which this condition is present in over 60% of patients [ 21 , 45 , 46 ]. However, at the later stages of the disease (i.e., in heavily pre-treated mCRPC), the prevalence of sarcopenia can be considerably increased [ 21 , 45 ]. Coherently, in the present study, all the enrolled patients met the radiological criteria for sarcopenia.…”

Section: Discussionmentioning

confidence: 99%

Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223

et al. 2022

View full text Add to dashboard Cite

Objective Androgen deprivation therapy alters body composition promoting a significant loss in skeletal muscle (SM) mass through inflammation and oxidative damage. We verified whether SM anthropometric composition and metabolism are associated with unfavourable overall survival (OS) in a retrospective cohort of metastatic castration-resistant prostate cancer (mCRPC) patients submitted to 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) imaging before receiving Radium-223. Patients and methods Low-dose CT were opportunistically analysed using a cross-sectional approach to calculate SM and adipose tissue areas at the third lumbar vertebra level. Moreover, a 3D computational method was used to extract psoas muscles to evaluate their volume, Hounsfield Units (HU) and FDG retention estimated by the standardized uptake value (SUV). Baseline established clinical, lab and imaging prognosticators were also recorded. Results SM area predicted OS at univariate analysis. However, this capability was not additive to the power of mean HU and maximum SUV of psoas muscles volume. These factors were thus combined in the Attenuation Metabolic Index (AMI) whose power was tested in a novel uni- and multivariable model. While Prostate-Specific Antigen (PSA), Alkaline Phosphatase (ALP), Lactate Dehydrogenase and Hemoglobin, Metabolic Tumor Volume, Total Lesion Glycolysis and AMI were associated with long-term OS at the univariate analyses, only PSA, ALP and AMI resulted in independent prognosticator at the multivariate analysis. Conclusion The present data suggest that assessing individual 'patients' SM metrics through an opportunistic operator-independent computational analysis of FDG PET/CT imaging provides prognostic insights in mCRPC patients candidates to receive Radium-223. Graphical abstract

show abstract

CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis

Cited by 9 publications

References 26 publications

Prognostic Role of the Pectoralis Musculature in Patients with COVID-19. A Multicenter Study

Prognostic Role of the Pectoralis Musculature in Patients with COVID-19. A Multicenter Study

Effects of β‐hydroxy β‐methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review

Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223

Contact Info

Product

Resources

About